Idalopirdine

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]

Idalopirdine
Clinical data
Other namesLu-AE-58054
ATC code
  • None
Identifiers
IUPAC name
  • 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.245.270
Chemical and physical data
FormulaC20H19F5N2O
Molar mass398.377 g·mol−1
3D model (JSmol)
SMILES
  • FC(F)C(F)(F)COc1cccc(c1)CNCCc3c[nH]c2cc(F)ccc23
InChI
  • InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2 N
  • Key:YBAWYTYNMZWMMJ-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]

See also

References
  1. "U.S. Development Programs". Lundbeck.
  2. "Search of: Lu AE58054 - List Results". ClinicalTrials.gov. National Library of Medicine, U.S. Department of Health and Human Services.
  3. Taylor NP (23 September 2016). "PhIII Alzheimer's flop takes chunk out of Lundbeck, hits Axovant with aftershocks".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.